FDA Action Affects Products Manufactured by Elite Pharmaceuticals, Inc.

NORTHVALE, N.J., March 4, 2011 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (OTCBB:ELTP) advises that the US Food and Drug Administration (FDA) announced that it intends to remove approximately 500 cough/cold and allergy related products from the U.S. market. Elite currently manufactures two of the drugs impacted by the FDA’s action which are marketed by ECR [...] http://bit.ly/euBM49